John Pippen

6.9k total citations · 2 hit papers
68 papers, 5.1k citations indexed

About

John Pippen is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, John Pippen has authored 68 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Oncology, 28 papers in Cancer Research and 21 papers in Pulmonary and Respiratory Medicine. Recurrent topics in John Pippen's work include Cancer Treatment and Pharmacology (30 papers), Breast Cancer Treatment Studies (25 papers) and HER2/EGFR in Cancer Research (24 papers). John Pippen is often cited by papers focused on Cancer Treatment and Pharmacology (30 papers), Breast Cancer Treatment Studies (25 papers) and HER2/EGFR in Cancer Research (24 papers). John Pippen collaborates with scholars based in United States, United Kingdom and Peru. John Pippen's co-authors include Joyce O’Shaughnessy, Debra A. Patt, C. R. Bradley, Stephen E. Jones, Joyce O’Shaughnessy, Frankie A. Holmes, Joanne L. Blum, Cynthia Osborne, Barry M. Sherman and Svetislava J. Vukelja and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

John Pippen

68 papers receiving 4.9k citations

Hit Papers

Lapatinib Combined With Letrozole Versus Letrozole and Pl... 2009 2026 2014 2020 2009 2011 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
    2009 766 citations Stephen Johnston, John Pippen et al. Journal of Clinical Oncology profile →
  2. Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
    2011 616 citations Joyce O’Shaughnessy, Cynthia Osborne et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Pippen United States 30 3.7k 1.8k 1.3k 1.1k 1.1k 68 5.1k
Beverly Moy United States 41 4.0k 1.1× 1.8k 1.0× 1.6k 1.3× 430 0.4× 696 0.6× 214 6.1k
Olivia Pagani Switzerland 42 3.4k 0.9× 1.8k 1.0× 1.5k 1.2× 1.3k 1.2× 667 0.6× 159 5.5k
Jeffrey S. Abrams United States 33 2.2k 0.6× 1.7k 0.9× 811 0.6× 1.3k 1.1× 494 0.5× 104 4.4k
Debra A. Patt United States 33 4.6k 1.2× 1.3k 0.7× 1.8k 1.4× 320 0.3× 1.2k 1.1× 122 6.2k
Steven E. Come United States 44 3.9k 1.1× 2.6k 1.4× 1.5k 1.2× 1.2k 1.1× 742 0.7× 166 6.7k
Francesco Perrone Italy 38 3.6k 1.0× 870 0.5× 1.8k 1.4× 430 0.4× 1.1k 1.0× 188 5.9k
Susana Banerjee United Kingdom 43 3.6k 1.0× 1.0k 0.6× 852 0.7× 1.0k 0.9× 2.1k 1.9× 307 7.0k
Nils Wilking Sweden 34 2.2k 0.6× 1.2k 0.7× 573 0.5× 1.3k 1.2× 654 0.6× 138 4.6k
Rachel A. Freedman United States 32 2.4k 0.7× 1.5k 0.8× 822 0.6× 535 0.5× 312 0.3× 186 4.0k
Erica L. Mayer United States 31 2.6k 0.7× 1.2k 0.7× 997 0.8× 495 0.5× 1.4k 1.3× 144 4.7k

Countries citing papers authored by John Pippen

Since Specialization
Citations

This map shows the geographic impact of John Pippen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Pippen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Pippen more than expected).

Fields of papers citing papers by John Pippen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Pippen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Pippen. The network helps show where John Pippen may publish in the future.

Co-authorship network of co-authors of John Pippen

This figure shows the co-authorship network connecting the top 25 collaborators of John Pippen. A scholar is included among the top collaborators of John Pippen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Pippen. John Pippen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pippen, John, et al.. (2019). A medical student perspective on solutions for burnout. Baylor University Medical Center Proceedings. 32(3). 452–455. 3 indexed citations
2.
Osborne, Cynthia R., et al.. (2019). Giant malignant phyllodes tumor with metastasis to the brain. Baylor University Medical Center Proceedings. 32(1). 116–118. 3 indexed citations
3.
Yang, Robert, et al.. (2018). Clinico-radiologic features and management of hematological tumors in the breast: a case series. Breast Cancer. 26(2). 244–248. 5 indexed citations
4.
O’Shaughnessy, Joyce, Hartmut Koeppen, Yuanyuan Xiao, et al.. (2015). Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine. Clinical Cancer Research. 21(19). 4305–4311. 37 indexed citations
5.
Holmes, Frankie A., Virginia Espina, Lance A. Liotta, et al.. (2013). Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling. BMC Research Notes. 6(1). 507–507. 50 indexed citations
6.
Santarpia, Libero, Yuan Qi, Katherine Stemke‐Hale, et al.. (2012). Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Research and Treatment. 134(1). 333–343. 94 indexed citations
7.
O’Shaughnessy, Joyce, Cynthia Osborne, John Pippen, et al.. (2011). Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer. New England Journal of Medicine. 364(3). 205–214. 616 indexed citations breakdown →
8.
Pippen, John, et al.. (2011). Inflammatory Breast Cancer: The Experience of Baylor University Medical Center at Dallas. Baylor University Medical Center Proceedings. 24(2). 86–88. 5 indexed citations
9.
Pippen, John, Devchand Paul, Svetislava J. Vukelja, Alicia Clawson, & José Iglesias. (2011). Dose-dense doxorubicin and cyclophosphamide followed by dose-dense albumin-bound paclitaxel plus bevacizumab is safe as adjuvant therapy in patients with early stage breast cancer. Breast Cancer Research and Treatment. 130(3). 825–831. 16 indexed citations
10.
Shiller, S. Michelle, et al.. (2011). The Sensitivity and Specificity of Sentinel Lymph Node Biopsy for Breast Cancer at Baylor University Medical Center at Dallas: A Retrospective Review of 488 Cases. Baylor University Medical Center Proceedings. 24(2). 81–85. 12 indexed citations
11.
Schneider, Reva, et al.. (2011). Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update. Breast Cancer Targets and Therapy. 3. 113–113. 31 indexed citations
12.
Iwamoto, Takayuki, Giampaolo Bianchini, Daniel J. Booser, et al.. (2010). Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer. JNCI Journal of the National Cancer Institute. 103(3). 264–272. 179 indexed citations
13.
Pippen, John, Anthony Elias, Marcus A. Neubauer, et al.. (2010). A Phase II Trial of Pemetrexed and Gemcitabine in Patients With Metastatic Breast Cancer Who Have Received Prior Taxane Therapy. Clinical Breast Cancer. 10(2). 148–153. 10 indexed citations
14.
Jones, Stephen E., Frankie A. Holmes, Joyce O’Shaughnessy, et al.. (2009). Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. Journal of Clinical Oncology. 27(8). 1177–1183. 400 indexed citations
15.
Johnston, Stephen, John Pippen, Xavier Pivot, et al.. (2009). Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer. Journal of Clinical Oncology. 27(33). 5538–5546. 766 indexed citations breakdown →
16.
Jones, Stephen E., Christopher Stokoe, Mark D. Sborov, et al.. (2008). The Effect of Tamoxifen or Exemestane on Bone Mineral Density During the First 2 Years of Adjuvant Treatment of Postmenopausal Women with Early Breast Cancer. Clinical Breast Cancer. 8(6). 527–532. 20 indexed citations
17.
Blum, Joanne L., Michael A. Savin, Gerald M. Edelman, et al.. (2007). Phase II Study of Weekly Albumin-Bound Paclitaxel for Patients with Metastatic Breast Cancer Heavily Pretreated with Taxanes. Clinical Breast Cancer. 7(11). 850–856. 136 indexed citations
18.
Nemunaitis, John, Casey Cunningham, Neil Senzer, et al.. (2005). Phase I Study of CT-2103, A Polymer-Conjugated Paclitaxel, and Carboplatin in Patients with Advanced Solid Tumors. Cancer Investigation. 23(8). 671–676. 32 indexed citations
19.
O’Shaughnessy, Joyce, et al.. (2004). Phase II Study of Trastuzumab plus Gemcitabine in Chemotherapy-Pretreated Patients with Metastatic Breast Cancer. Clinical Breast Cancer. 5(2). 142–147. 73 indexed citations
20.
Nemunaitis, John, Timothy Fong, Francis Burrows, et al.. (1999). Phase I Trial of Interferon gamma Retroviral Vector Administered Intratumorally with Multiple Courses in Patients with Metastatic Melanoma. Human Gene Therapy. 10(8). 1289–1298. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Beverly Moy Breakdown of academic impact, for papers by Olivia Pagani Breakdown of academic impact, for papers by Jeffrey S. Abrams Breakdown of academic impact, for papers by Debra A. Patt Breakdown of academic impact, for papers by Steven E. Come Breakdown of academic impact, for papers by Francesco Perrone Breakdown of academic impact, for papers by Susana Banerjee Breakdown of academic impact, for papers by Nils Wilking Breakdown of academic impact, for papers by Rachel A. Freedman Breakdown of academic impact, for papers by Erica L. Mayer
Rankless by CCL
2026